Lv1
10 积分 2026-03-30 加入
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
19小时前
已完结
Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents
1天前
已完结
Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
1天前
已完结
Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study
1天前
已完结
皖公网安备34019202002308
